Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.

Percentage of patients hospitalized whatever the reason

Time frame: Month 1 and 3

Percentage of patients with an WHO score >= 5

Time frame: Month 1

Percentage of patients staying in an Intensive Care Unit in the month following symptoms' onset

Time frame: Month 1

Percentage of patients who died from COVID-19 complications and any other reason

Time frame: Month 1

Percentage of patients presenting a adverse event and percentage of treatment discontinuation caused by those adverse events

Time frame: Month 1

Time between first symptoms and treatment and the reasons for this delay

Time frame: Day 0

Virological response

Percentage of virological response defined by CT\>=31 or negative PCR test +

Time frame: Day 7 for ambulatory patients, Day 3, 5 and 7 for hospitalized patients

Virological criteria linked to the emergence of resistance

Percentage of patients included developing resistance variants, genotypic and phenotypic characterization of resistance variants

Time frame: from inclusion until a negative PCR test or Ct ≥31 is obtained

Percentage of patients with positive anti-N and anti-S serology

Time frame: Day 0 and Month 3

anti-S antibody level

Time frame: Day 0 and Month 3

Flow cytometry cartography of myeloid response

Flow cytometry cartography of myeloid (functional subtypes of monocytes and dendritic cells) response

Time frame: Day 0, 7 and Month 1

Flow cytometry cartography of T-lymphocyte response

Flow cytometry cartography of T-lymphocyte (conventional T-lymphocytes by identifying naïve, memory and effector Th1, Th2, Tfh and Th17 T-lymphocytes, NK and gamma-delta T-lymphocytes, regulatory T-lymphocytes; surface and intracellular markers) response

Time frame: Day 0, 7 and Month 1

Flow cytometry cartography of B-lymphocyte response

Flow cytometry cartography of B-lymphocyte (transitional, naïve, memory T-lymphocyte with or without isotypic switching, plasmablasts) response

Time frame: Day 0, 7 and Month 1

Dosing of a wide range of cytokines and chemokines (IFNalpha, IFNgamma, IL-6, IL-1, IL-8, IL-15, IL-18, IL1-RA, IL-7, IL-10, CXCL10, CXCL13, CCL2 and CCL3) using the Meso Scale Discovery approach

Time frame: Day 0, 7 and Month 1

Clinical and biological predictors (clinical parameters, treatment received, virological criteria (cycle threshold (CT), variants) of the onset of complications from COVID19, hospitalization, death

Identication of clinical and biological predictors of the onset of complications from COVID19, hospitalization, death by a logistic model or survival model (RMST): the response variable is the occurrence of a complication, hospitalization, death or the average survival at 1 month on these different criteria; the covariates are the parameters at inclusion, the treatment received, the virological criteria (CT, variants) which can be considered as a time-dependent covariate

Time frame: from inclusion until the end of the follow-up (Month 1 or Month 3)

Clinical and biological predictive factors (clinical parameters, treatment received, virological criteria (cycle threshold (CT), variants)) linked to the neutralizing serological response: non-response, duration of the response

Identification of clinical and biological predictive factors (clinical parameters, treatment received, virological criteria (cycle threshold (CT), variants)) linked to the neutralizing serological response: non-response, duration of the response by a logistic model or mixed model for repeated measures

Time frame: from inclusion until the end of the follow-up (Month 1 or Month 3)

Clinical and biological predictors (clinical parameters, treatment received, virological criteria) of viral response (viral genotypes, emergence of resistant strains)

Identification of clinical and biological predictive factors related to the virological response (viral genotypes, emergence of resistant strains) by a logistic model: the response variable is RT-PCR negativation at D7 (or CT≥31), the covariates are the parameters at inclusion, the treatment received, the virological criteria at baseline

Time frame: from inclusion until the end of the follow-up (Month 1 or Month 3)